Research Topics
| L H MillerSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Malaria biology and disease pathogenesis: insights for new treatmentsLouis H Miller
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, USA
Nat Med 19:156-67. 2013..There is also a need for new therapies to reduce the high mortality of severe malaria. An understanding of the pathophysiology of severe disease may identify rational targets for drugs that improve survival...
Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccineAmed Ouattara
Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Dentistry, Bamako, Mali
Malar J 9:175. 2010....- The Multilateral Initiative on Malaria: looking back and looking aheadLouis H Miller
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
Trends Parasitol 26:110-3. 2010.... - Artemisinin: discovery from the Chinese herbal gardenLouis H Miller
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
Cell 146:855-8. 2011.... 
Evolution of the human genome under selective pressure from malaria: applications for controlL H Miller
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 0425, USA
Parassitologia 41:77-82. 1999..Much of the work has important implications both for understanding pathogenesis and for applications for control of disease...- Definition of the minimal domain of CIDR1alpha of Plasmodium falciparum PfEMP1 for binding CD36Louis H Miller
Malaria Vaccine Development Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Twinbrook I, 5640 Fishers Lane, Rockville, MD 20852, USA
Mol Biochem Parasitol 120:321-3. 2002 - Classification of adhesive domains in the Plasmodium falciparum erythrocyte membrane protein 1 familyJ D Smith
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
Mol Biochem Parasitol 110:293-310. 2000..This information might be used to develop interventions targeting parasite binding variants that cause disease... - The surface variant antigens of Plasmodium falciparum contain cross-reactive epitopesB Gamain
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 4 Center Drive MSC 0425, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 98:2664-9. 2001..The demonstration of cross-reactive epitopes on the PE surface provides further credence for development of effective vaccines against the variant antigen on the surface of P. falciparum-infected erythrocytes... - CD36 peptides that block cytoadherence define the CD36 binding region for Plasmodium falciparum-infected erythrocytesD I Baruch
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
Blood 94:2121-7. 1999..falciparum PE. Adherence blocking peptides from this region may be useful for modeling the PE/PfEMP1 interaction with CD36 and for development of potential anti-adhesion therapeutics... - Modifications in the CD36 binding domain of the Plasmodium falciparum variant antigen are responsible for the inability of chondroitin sulfate A adherent parasites to bind CD36B Gamain
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
Blood 97:3268-74. 2001..These findings provide a molecular explanation for the inability of placental sequestered parasites to bind CD36 and provide additional insight into critical residues for the CIDR-1/CD36 interaction... - Characterization of a Plasmodium falciparum erythrocyte-binding protein paralogous to EBA-175D C Mayer
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 4 Center Drive, Room 4/126, Bethesda, MD 20892-0425, USA
Proc Natl Acad Sci U S A 98:5222-7. 2001..The interest in BAEBL's reduced binding to Gerbich erythrocytes derives from the high frequency of the Gerbich phenotype in some regions of Papua New Guinea where P. falciparum is hyperendemic... - P. falciparum rosetting mediated by a parasite-variant erythrocyte membrane protein and complement-receptor 1J A Rowe
Laboratory of Parasitic Diseases, NIAID, NIH, Bethesda, Maryland 20892, USA
Nature 388:292-5. 1997..Thus we describe a new adhesive function for PfEMP1 and raise the possibility that CR1 polymorphisms in Africans that influence the interaction between erythrocytes and PfEMP1 may protect against severe malaria... - Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trialA W Stowers
Malaria Vaccine Development Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Inc, Rockville, Maryland 20852, USA
Infect Immun 69:1536-46. 2001..Vaccine formulation in an alternate adjuvant, MF59, resulted in significantly lower antibody titers and no protection... - Are trials in New World monkeys on the critical path for blood-stage malaria vaccine development?A W Stowers
Malaria Vaccine Development Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infections Diseases, National Institutes of Health, Rockville, MD 20852, USA
Trends Parasitol 17:415-9. 2001..Here, we argue that first proving efficacy in the New World monkey challenge model would accelerate development... - International union of pharmacology. XXII. Nomenclature for chemokine receptorsP M Murphy
Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
Pharmacol Rev 52:145-76. 2000.... - Evidence implicating MHC genes in the immunological nonresponsiveness to the Plasmodium falciparum CS proteinM F Good
Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, MD
Bull World Health Organ 68:80-4. 1990.... - Plasmodium falciparum protein associated with the invasion junction contains a conserved oxidoreductase domainD E Hudson-Taylor
Laboratory of Malaria Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
Mol Microbiol 15:463-71. 1995..By virtue of its positive charge, the C-terminal domain resembles domains in some cytoskeleton-associated proteins and may mediate the interaction of MCP-1 with cytoskeleton in Plasmodium... - Plasmodium gallinaceum: differential killing of some mosquito stages of the parasite by insect defensinM Shahabuddin
Medical Entomology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
Exp Parasitol 89:103-12. 1998.... - Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25Joanna Kubler Kielb
Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, 31 Center Drive, MSC 2423, Bethesda, MD 20892 2520, USA
Proc Natl Acad Sci U S A 104:293-8. 2007..The observed transmission-blocking activity of immune sera correlated with antibody levels measured by ELISA... - Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complexYimin Wu
Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
Proc Natl Acad Sci U S A 103:18243-8. 2006..Protein antigen conjugation to OMPC or other protein carrier may have general application to a spectrum of protein subunit vaccines to increase immunogenicity without the need for potentially reactogenic adjuvants... - Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activitySanjay Singh
Antigen Research Section, Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases National Institutes of Health, TW1, Rockville, Maryland 20852, USA
Infect Immun 74:4573-80. 2006.... - The glycophorin C N-linked glycan is a critical component of the ligand for the Plasmodium falciparum erythrocyte receptor BAEBLD C Ghislaine Mayer
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
Proc Natl Acad Sci U S A 103:2358-62. 2006..falciparum to recognize oligosaccharides on different erythrocyte surface glycoproteins or glycolipids, greatly increasing its invasion range... - Immunization of Aotus monkeys with recombinant cysteine-rich interdomain region 1 alpha protects against severe disease during Plasmodium falciparum reinfectionMorris O Makobongo
Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland 20852, USA
J Infect Dis 193:731-40. 2006..Such vaccination may function by priming for the accelerated acquisition of immunity to new PfEMP1 variants... - Plasmodium vivax: transmission-blocking immunity in a malaria-endemic area of ColombiaMyriam Arevalo-Herrera
Instituto de Inmunología del Valle, Cali, Colombia
Am J Trop Med Hyg 73:38-43. 2005..This activity disappeared at a 1:4 dilution in most sera tested. Afro-Colombian individuals showed lower activity than other ethnic groups and febrile patients produced stronger inhibition than those without fever... - Upregulation of expression of the reticulocyte homology gene 4 in the Plasmodium falciparum clone Dd2 is associated with a switch in the erythrocyte invasion pathwayDeepak Gaur
Laboratory of Malaria and Vector Research (LMVR, National Institutes of Allergy and Infectious Diseases/NIH, 12735 Twinbrook Parkway, Building Twinbrook III/Room 3E-32D, Bethesda, MD 20892-8132, USA
Mol Biochem Parasitol 145:205-15. 2006..As Dd2(NM) is a selected subclone of Dd2, the marked upregulation of PfRH4 expression in Dd2(NM) suggests its role in erythrocyte invasion through the sialic acid independent pathway of Dd2(NM)... - Plasmodium falciparum: characterization of a late asexual stage golgi protein containing both ankyrin and DHHC domainsKarl B Seydel
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Exp Parasitol 110:389-93. 2005..falciparum. The timing of expression as well as the location of this protein suggests that it may play an important role in the sorting of proteins to the apical organelles during the development of the asexual stage of the parasite... - posttranslational modification of recombinant Plasmodium falciparum apical membrane antigen 1: impact on functional immune responses to a malaria vaccine candidateBirgitte Giersing
Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, Twinbrook I, Room 1210A, 5640 Fisher Lane, Rockville, Maryland 20852, USA
Infect Immun 73:3963-70. 2005..coli- and P. pastoris-derived antigens are immunologically and functionally equivalent and are unaffected by the posttranslational modification resulting from expression in these two systems... - Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malariaElissa M Malkin
Johns Hopkins University Bloomberg School of Public Health, Center for Immunization Research, 624 N Broadway, Room 217, Baltimore, MD 21205, USA
Infect Immun 73:3677-85. 2005..To our knowledge, this is the first AMA1 vaccine candidate to elicit functional immune responses in malaria-naive humans, and our results support the further development of this vaccine... - Overproduction of Pichia pastoris or Plasmodium falciparum protein disulfide isomerase affects expression, folding and O-linked glycosylation of a malaria vaccine candidate expressed in P. pastorisChiawei W Tsai
Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Disease, National Institutes of Health, 5640 Fishers Lane, Rockville, MD 20852, USA
J Biotechnol 121:458-70. 2006..The overproduction of PpPDI or PfPDI provides new platforms for expression of disulfide-rich malaria proteins... - In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunizedKazutoyo Miura
Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA
Infect Immun 75:5827-36. 2007.... - The cysteine-rich interdomain region from the highly variable plasmodium falciparum erythrocyte membrane protein-1 exhibits a conserved structureMichael M Klein
Structural Biology Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America
PLoS Pathog 4:e1000147. 2008..This new understanding of PfEMP1 structure will allow the use of better-defined PfEMP1 domains for functional studies, for the design of candidate vaccines, and for understanding the molecular basis of cytoadherence... - Erythrocyte binding protein PfRH5 polymorphisms determine species-specific pathways of Plasmodium falciparum invasionKaren Hayton
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892 8132, USA
Cell Host Microbe 4:40-51. 2008..nancymaae erythrocytes. Our results also suggest that PfRH5 is a parasite ligand for human infection, and that amino acid substitutions can cause its binding domain to recognize different human erythrocyte surface receptors... - Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51Yimin Wu
Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, United States of America
PLoS ONE 3:e2636. 2008..This single blinded, dose escalating, controlled Phase 1 study assessed the safety and immunogenicity of recombinant Pfs25 and Pvs25 formulated with Montanide ISA 51, a water-in-oil emulsion... - Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of respondersFeng Qian
Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
Vaccine 26:2521-7. 2008..The results obtained in this study indicate the potential use of a combination strategy to increase the number of responders to malarial antigens in humans... - Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian childrenAlassane Dicko
Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Dentistry, University of Bamako, Bamako, Mali
PLoS ONE 3:e1563. 2008..The aim of this study was to assess the safety and immunogenicity of this vaccine in young children in a malaria endemic area... - Ex vivo cytokine and memory T cell responses to the 42-kDa fragment of Plasmodium falciparum merozoite surface protein-1 in vaccinated volunteersMaria Cecilia Huaman
Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 12735 Twinbrook Parkway, Rockville, MD 20852, USA
J Immunol 180:1451-61. 2008..The identification of human-specific CD4(+) memory T cells provides the foundation for future studies of these cells both after vaccination and in field studies... - Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccinesKazutoyo Miura
Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
Vaccine 26:193-200. 2008..Since this ELISA method gives reliable antibody titer with less labor than other methods, it can strongly support vaccine development... - Mononeme: a new secretory organelle in Plasmodium falciparum merozoites identified by localization of rhomboid-1 proteaseSubhash Singh
Malaria Cell Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 12735 Twinbrook Parkway, Rockville, MD 20852, USA
Proc Natl Acad Sci U S A 104:20043-8. 2007..We have named this single thread-like organelle in merozoites, the mononeme... - Recombinant Plasmodium falciparum reticulocyte homology protein 4 binds to erythrocytes and blocks invasionDeepak Gaur
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Twinbrook III, 12735 Twinbrook Parkway, Bethesda, MD 20892 8132, USA
Proc Natl Acad Sci U S A 104:17789-94. 2007..These findings suggest that, although PfRH4 is required for invasion of neuraminidase-treated erythrocytes by Dd2/NM, it is inaccessible for antibody-mediated inhibition of the invasion process... - Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult MaliansAlassane Dicko
Malaria Research and Training Center, Department of Hematology, University of Bamako, Bamako, Mali
PLoS ONE 2:e1045. 2007..After a peak 14 days following the second vaccination, antibody levels decreased to baseline levels one year later at the time of the third vaccination that induced little or no increase in antibody levels... - Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidatesFeng Qian
Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Rockville, MD 20852, USA
Vaccine 25:3923-33. 2007..These conjugates now need to be tested in humans to determine if mice are predictive of the response in humans... - Improved yield of recombinant merozoite Surface protein 3 (MSP3) from Pichia pastoris using chemically defined mediaJin Wang
Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Rockville, Maryland 20852, USA
Biotechnol Bioeng 90:838-47. 2005..pastoris biomass generated at a high specific growth rate (0.04/h) nor low induction temperatures during induction improved yield. Nitrogen source was the most important factor affecting expression of MSP3 in defined media... - Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malariaElissa M Malkin
Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Twinbrook 1, Room 1123, Rockville, MD 20852, USA
Vaccine 23:3131-8. 2005..Pvs25H generates transmission blocking immunity in humans against P. vivax demonstrating the potential of this antigen as a component of a transmission blocking vaccine... - Progress in the development of recombinant and synthetic blood-stage malaria vaccinesSiddhartha Mahanty
Malaria Vaccine Development Unit, NIAID, NIH, Twin Brook I, 5640 Fishers Lane, Rockville, MD 20852, USA
J Exp Biol 206:3781-8. 2003..Results from trials of asexual blood stage vaccine that support the continued effort to develop these antigens as key ingredients of multicomponent, multistage malaria vaccines are documented... - DNA immunization with the cysteine-rich interdomain region 1 of the Plasmodium falciparum variant antigen elicits limited cross-reactive antibody responsesDror I Baruch
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
Infect Immun 71:4536-43. 2003..These sera also appeared to give limited low-titer variant transcending agglutination. Thus, DNA immunization appears to be a very useful tool for developing variant antigen vaccines... - Polymorphism in a Plasmodium falciparum erythrocyte-binding ligand changes its receptor specificityD C Ghislaine Mayer
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 4 Center Drive, Building 4 Room B1-41, Bethesda, MD 20892, USA
J Exp Med 196:1523-8. 2002..These results suggest that P. falciparum has evolved multiple invasion pathways dependent on polymorphisms in the BAEBL ligand... - Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malariaAnthony W Stowers
Malaria Vaccine Development Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland 20852, USA
Infect Immun 70:6961-7. 2002..The protection induced by a combination vaccine of AMA1 and MSP1 was not superior to the protection obtained with AMA1 alone, although the immunity generated appeared to operate against both vaccine components... - In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic responseMichael C Kennedy
Malaria Vaccine Development Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland 20852, USA
Infect Immun 70:6948-60. 2002.... - Malaria--a shadow over AfricaLouis H Miller
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA
Science 298:121-2. 2002..The completed genomes of Plasmodium falciparum and its vector Anopheles gambiae represent a big step toward the discovery of these needed tools... - A high malaria reinfection rate in children and young adults living under a low entomological inoculation rate in a periurban area of Bamako, MaliIssaka Sagara
Malaria Research and Training Center, Departement d'Epidemiologie des Affections Parasitaires, , de Pharmacie et d'Odonto-Stomatologie, , Bamako
Am J Trop Med Hyg 66:310-3. 2002..5 infected bites/person/month. The finding that reinfection rates were high despite low EIRs suggests that a low EIR may be sufficient to support small sample size vaccine efficacy trials in mesoendemic areas... - Molecular basis for the dichotomy in Plasmodium falciparum adhesion to CD36 and chondroitin sulfate ABenoit Gamain
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 99:10020-4. 2002..Furthermore, we propose a model explaining the requirement for structural dichotomy between placental and nonplacental isolates... - Aotus New World monkeys: model for studying malaria-induced anemiaAndrea F Egan
Malaria Vaccines Section and Malaria Vaccine Development Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Blood 99:3863-6. 2002..We demonstrate that Aotus monkeys are a nonhuman primate model to gain insight into the pathogenesis of severe anemia in African children... - Immunization of Aotus monkeys with a functional domain of the Plasmodium falciparum variant antigen induces protection against a lethal parasite lineDror I Baruch
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 99:3860-5. 2002..The level of protection and the evidence of boosting during infection encourage further exploration of this concept for malaria vaccine development... - Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeysHajime Hisaeda
Malaria Vaccine Development Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases/NIH, Rockville, MD 20852, USA
J Infect Dis 185:657-64. 2002..In the MSP3-vaccinated group, protection correlated with prechallenge titers of antibody to MSP3. In the MSP1 and control groups, protection correlated with antibody to MSP3 raised by challenge infection... - The pathogenic basis of malariaLouis H Miller
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
Nature 415:673-9. 2002..The inability of many countries to fund expensive campaigns and antimalarial treatment requires these tools to be highly effective and affordable... - Two worlds of malariaThomas E Wellems
National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
N Engl J Med 349:1496-8. 2003 - Induction of crossreactive antibodies against the Plasmodium falciparum variant proteinSylvie Gratepanche
Malaria Vaccine Development Unit, National Institute of Allergy and Infectious Diseases/National Institutes of Health, Rockville, MD 20852, USA
Proc Natl Acad Sci U S A 100:13007-12. 2003..The induced crossreactivity suggests that an anti-PfEMP1 vaccine may be possible... - Domain III of Plasmodium falciparum apical membrane antigen 1 binds to the erythrocyte membrane protein KxKentaro Kato
Laboratory of Malaria and Vector Research and Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 8132, USA
Proc Natl Acad Sci U S A 102:5552-7. 2005.... - Identification of multiple chondroitin sulfate A (CSA)-binding domains in the var2CSA gene transcribed in CSA-binding parasitesBenoit Gamain
Unité de Biologie des Interactions Hôte Parasite, URA 2581, Institut Pasteur, Paris, France
J Infect Dis 191:1010-3. 2005..The identification of multiple binding domains in var2CSA strengthens the evidence for their involvement in malaria during pregnancy and may have applications for the development of a vaccine against malaria in pregnancy... - Parasite ligand-host receptor interactions during invasion of erythrocytes by Plasmodium merozoitesDeepak Gaur
Laboratory of Malaria and Vector Research, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, 12735 Twinbrook Parkway, Building Twinbrook III/Room 3E-32D, Bethesda, MD 20892-8132, USA
Int J Parasitol 34:1413-29. 2004..Here we review the current state of knowledge about the receptor-ligand interactions that mediate merozoite invasion of erythrocytes... - Identification of a 67-amino-acid region of the Plasmodium falciparum variant surface antigen that binds chondroitin sulphate A and elicits antibodies reactive with the surface of placental isolatesBenoit Gamain
Laboratory of Molecular and Vector Research, NIAID, NIH, Bethesda, MD 20892 0425, USA
Mol Microbiol 53:445-55. 2004..The identification of a minimal binding region from a highly variable cytoadherent family may have application for a vaccine against malaria in pregnancy... - Plasmodium falciparum cysteine protease falcipain-1 is not essential in erythrocytic stage malaria parasitesPuran S Sijwali
Department of Medicine, San Francisco General Hospital, University of California, San Francisco, CA 94143-0811, USA
Proc Natl Acad Sci U S A 101:8721-6. 2004..Our results indicate that although falcipain-1 is expressed by erythrocytic parasites, it is not essential for normal development during this stage or for erythrocyte invasion... - A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparumAnthony W Stowers
Malaria Vaccine Development Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Rockville, MD 20852, USA
Proc Natl Acad Sci U S A 99:339-44. 2002..This study demonstrates the potential for producing efficacious malarial vaccines in transgenic animals... - Polymorphism in the Plasmodium falciparum erythrocyte-binding ligand JESEBL/EBA-181 alters its receptor specificityD C Ghislaine Mayer
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 4 Center Drive, Room 4126, Bethesda, MD 20892-0425, USA
Proc Natl Acad Sci U S A 101:2518-23. 2004..falciparum may have been successful in endemic areas because it has mutated the ligands of the DBL family to create multiple pathways of invasion, thus making selection of refractory erythrocytes unlikely... - Infected erythrocyte binding to hyaluronic acid and malaria in pregnant womenJoseph D Smith
J Infect Dis 189:165-8. 2004 - Plasmodium biology: genomic gleaningsL Aravind
National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, USA
Cell 115:771-85. 2003..Plasmodium possesses many cell surface molecules with "animal-like" adhesion modules. Potential genetic footprints of the ancestral eukaryotic algal precursor of the apicoplast are also detectable in its genome... - Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1Sanjay Singh
Malaria Vaccine Development Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland 20852, USA
Infect Immun 71:6766-74. 2003..falciparum. The protection correlated with antibody-dependent mechanisms. Thus, this new construct, E. coli MSP1(42), is a viable candidate for human vaccine trials... - Plasmodium falciparum is able to invade erythrocytes through a trypsin-resistant pathway independent of glycophorin BDeepak Gaur
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
Infect Immun 71:6742-6. 2003..Thus, P. falciparum is able to invade erythrocytes through a glycophorin B-independent, trypsin-resistant pathway... - Year-to-year variation in the age-specific incidence of clinical malaria in two potential vaccine testing sites in Mali with different levels of malaria transmission intensityAlassane Dicko
Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Odonto Stomatology, University of Bamako, Bamako, Mali
Am J Trop Med Hyg 77:1028-33. 2007..Our results suggest that, although the age distribution of clinical malaria depends on transmission intensity, the total burden of disease may be similar or higher in settings of low transmission... - Revisiting Freund's incomplete adjuvant for vaccines in the developing worldLouis H Miller
Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Twinbrook 1, 5640 Fishers Lane, Rockville, MD 20818, USA
Trends Parasitol 21:412-4. 2005.... - The etiology of severe anemia in a village and a periurban area in MaliAlassane Dicko
Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Odonto-Stomatology, University of Bamako, PO Box 1805, Bamako, Mali
Blood 104:1198-200. 2004..2 years of age. Raising the baseline hemoglobin level and lowering peak parasitemia in infants and young children may reduce the incidence of severe anemia resulting from malarial infection...